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Cadherin–catenin complexes play a critical role in intercellular adhesion, and their altered expression has been implicated in tumour
progression. In this study, the expression of E-cadherin, P-cadherin and b-catenin was analysed in 65 canine malignant mammary
tumours and correlated with clinicopathological parameters, proliferation and survival. Reduction in E-cadherin expression was signifi-
cantly associated with increased tumour size, high histological and invasion grades, lymph node metastasis and high mitotic index.
Reduced b-catenin expression was associated with high histological and invasion grades. Anomalous expression of P-cadherin was only
associated with invasion. In 39 cases for which follow-up data were available, reduced E-cadherin and b-catenin expression was signif-
icantly associated with shorter overall survival and disease free survival. Abnormal expression of adhesion molecules is a common phe-
nomenon in canine mammary malignant tumours and may play a central role in tumour progression.
 2007 Elsevier Ltd. All rights reserved.
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Cadherins are calcium-dependent cell–cell adhesion
molecules that play critical roles during embryogenesis
and in the maintenance of normal adult tissue architecture
(Takeichi, 1991; Gumbiner, 1996). Cadherins interact with
several proteins termed catenins, including a-, b- and c-
catenin, which link cadherins to the actin cytoskeleton
and mediate signal-transduction mechanisms that control1090-0233/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tvjl.2007.05.024
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E-mail address: fernando.schmitt@ipatimup.pt (F. Schmitt).cellular events, including cell polarity, differentiation,
growth and migration (Knudsen et al., 1998).
The best characterised and most widely distributed
members of the family are the classical cadherins, namely
epithelial (E-) and placental (P-) cadherins (Nose and
Takeichi, 1986). E-cadherin is found in almost all human
epithelial tissues, whereas P-cadherin is restricted to the
basal layers of stratified epithelium (Nose and Takeichi,
1986; Shimoyama et al., 1989). In normal human breast
and canine mammary tissue, these molecules show a dis-
tinct pattern of expression; E-cadherin is expressed by
luminal epithelial cells, whereas expression of P-cadherin
is restricted to myoepithelial cells (Shimoyama et al.,
1989; Palacios et al., 1995; Gama et al., 2002, 2004).
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plexes is associated with oncogenic progression in human
breast cancer (Gamallo et al., 1993; Yoshida et al., 2001).
In addition, anomalous epithelial expression of P-cadherin
in human breast cancer is associated with aggressive bio-
logical behaviour and poor outcome (Palacios et al.,
1995; Peralta Soler et al., 1999; Paredes et al., 2002, 2005).
The role of cadherins and catenins in canine mammary
tumours is still poorly understood (Restucci et al., 1997;
Reis et al., 2003; Brunetti et al., 2005; De Matos et al.,
2007). Brunetti et al. (2005) showed that reduced E-cad-
herin/b-catenin expression influences invasion of canine
mammary tumours, but not proliferation or survival. Loss
of E-cadherin in canine mammary tumours was correlated
with tumour size, ulceration, lymph node metastasis,
necrosis and infiltrative growth (Matos et al., 2006).
Recently, we found a significant association between P-
cadherin expression in canine mammary tumours and his-
tological type (Gama et al., 2004). In the present study,
we correlated the expression of E- and P-cadherin and b-
catenin in a series of malignant canine mammary tumours
with clinicopathological parameters, proliferation and sur-
vival to study their possible role in canine mammary
tumorigenesis.Materials and methods
Source of tumours
Sixty-five malignant canine mammary tumours were selected from the
histopathological files of the University of Tra´s-os-Montes and Alto
Douro, Vila Real and from the Institute of Biomedical Science at the
University of Porto, Portugal. The material had been fixed in 10% neutral
buffered formalin and embedded in paraffin wax. Sections (3 lm) were cut
and stained with haematoxylin and eosin (HE) for histological examina-
tion and immunohistochemistry.Case follow-up
Follow-up data were available for 39 cases for a mean of 15 months
(range 1–36 months) after surgical treatment. Disease-free survival (DFS)
and overall survival (OS) were calculated from the day of the surgery until
the time of recurrence/metastasis or death, respectively. The cause of
death was confirmed at post-mortem examination.Histopathological examination
Tumours were classified according to the World Health Organization
(WHO) criteria for canine mammary neoplasms (Misdorp et al., 1999) by
three pathologists. Each tumour was assessed for size, skin ulceration,
necrosis and mode of growth (expansile vs. infiltrative). Regional lymph
nodes were available in 52 cases and assessed for the presence of
metastases.
Malignant epithelial neoplasms were graded according to the Not-
tingham method for human breast tumours (Elston and Ellis, 1998).
Tubule formation, nuclear pleomorphism and mitotic index were scored
on a scale of 1–3 (slight, moderate or marked degree) and grades were
based on the total score: grade I (well differentiated): 3–5 points; grade II
(moderately differentiated): 6–7 points; and grade III (poorly differenti-
ated): 8–9 points. Tumours were also graded for invasion according to
Gilbertson et al. (1983): stage 0 (non-infiltrating); stage I (stromal inva-sion); and stage II (neoplastic emboli in vessels and/or lymph node
involvement).
Immunohistochemistry
Monoclonal antibodies used in the present study were anti-E-cadherin
(4A2C7, 1:100, Zymed Laboratory), anti-P-cadherin (clone 56, 1:50, BD
Transduction Laboratories), anti-b-catenin (CAT-5H10, 1:100, Zymed
Laboratory) and anti-Ki-67 (MIB-1, 1:50, Dakocytomation). A strepta-
vidin–biotin-peroxidase complex method was used with a commercial
detection system (Ultra Vision Detection System, Lab Vision Corpora-
tion) following the manufacturer’s instructions.
Antigen retrieval for E-cadherin and b-catenin was carried out by
microwave treatment in a 0.05% detergent solution (Extran, Merck) and
for P-cadherin with ethylene diamine tetraacetic acid (EDTA) buffer pH
8.0 (Lab Vision Corporation) in a boiling water bath for 20 min. For Ki-
67 antigen retrieval, slides were incubated with 0.2 mg/mL trypsin (Merck)
in phosphate buffered saline (PBS) for 10 min at 37 C prior to microwave
treatment (3 · 5 min) in 10 mM citrate buffer, pH 6.0. Adjacent normal
mammary tissues were used as internal positive controls. The primary
antibody was replaced with PBS for negative controls.
Quantification of immunolabelling
P-cadherin expression in canine mammary tissues was assessed semi-
quantitatively according to the percentage of immunoreactive cells (cells
showing a membranous and/or cytoplasmic expression pattern) in nega-
tive (0: <10%) and positive (1: 10–25%; 2: 26–50%; 3: >50%) tumours
(Gama et al., 2004). E-cadherin and b-catenin immunoreactivity was
classified as membranous (localised at cell–cell boundaries) or cytoplasmic
(uniformly distributed through the cytoplasm, with no recognisable dis-
tinction between membrane and cytoplasm). Nuclear expression of b-
catenin was only detected in normal mammary gland epithelial cells
adjacent to the tumour in two cases and therefore was not scored. Cases
were grouped according to Brunetti et al. (2005) as ‘‘preserved’’, when
positivity was membranous and higher than 75% of neoplastic epithelial
cells and as ‘‘reduced’’ in all remaining samples, including negative
tumours.
Combined variables were created for immunoreactivity patterns of E-
cadherin/b-catenin (E-cad/b-cat), E-cadherin/P-cadherin (E-cad/P-cad)
and b-catenin/P-cadherin (b-cat/P-cad) to investigate a possible relation-
ship between any reduction/lack of expression of E-cadherin/b-catenin
and over-expression of P-cadherin. Tumours were classified into four
categories (+/+, +/, /+, /) for each combined variable.
Proliferative indices
Mitotic index and Ki-67 index were determined by counting 1000
neoplastic cells in the most mitotically active areas or areas with the
highest Ki-67 positivity and were calculated as the percentage of tumour
cells that exhibited mitotic figures or had positive staining for Ki-67,
respectively.
Statistical analysis
For statistical analysis, associations between the expression of the dif-
ferent adhesion molecules and continuous variables (mitotic and Ki-67
indices) were assessed by analysis of variance (ANOVA). Associations
between adhesion molecule expression and clinicopathological parameters
(categorical variables), such as tumour size, histological type, histological
grade and invasion, were performed using the v2 test. Fisher’s exact test was
performed when compared variables had exactly two groups (2 · 2 table),
such as E-cadherin expression (preserved and reduced groups) versus
ulceration (absent and present groups). Survival curves were generated by
the Kaplan–Meyer method and the survival rates were compared using the
log-rank test. All statistical analysis was performed using SPSS 11.5 statis-
tical software. P values <0.05 were considered statistically significant.
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The 65 malignant tumours examined in this study were
classified as solid carcinomas (22 cases), tubulopapillary
carcinomas (12), complex carcinomas (12), carcinosarco-
mas (12), spindle cell carcinomas (four) and sarcomas
(three) according to WHO criteria. Epithelial tumours were
classified as grade I (four cases), grade II (18) and grade III
(40) according to the Nottingham method.
Expression of P-cadherin was evident in all histological
types, whereas expression of E-cadherin and b-catenin was
negative in all sarcomas. Reduction/lack of E-cadherin
expression was evident in 27 malignant tumours (41.5%)
and reduction/lack of b-catenin expression in 35 (53.8%).
Aberrant cytoplasmic/membranous expression of P-cad-
herin was found in 56 (86.2%) malignant tumours. In 13
(20%) of these 56 tumours, 10–25% of neoplastic cells wereFig. 1. Immunohistochemical expression of adhesion molecules in malignant c
membranous E-cadherin expression. (B) Solid carcinoma. Neoplastic cells are
are positive. (C) Solid carcinoma, with strong P-cadherin immunoreactivity. (D
(Bar = 30 lm).positive; in 17 (26.2%), 26–50% were positive; and in 26
(40%) >50% were positive (Fig. 1).
Immunohistochemical expression of E-cadherin and b-
catenin was significantly correlated (P < 0.0001): 26 cases
were positive for both proteins, there was reduced expres-
sion of both proteins in 23 cases and 16 cases were discor-
dant. We found no significant association between aberrant
P-cadherin expression and reduced E-cadherin or b-catenin
expression.
The relationship between cadherins and b-catenin
expression and several clinicopathological variables is
shown in Table 1. There was a significant difference across
histological types in expression of E-cadherin (P = 0.01).
Reduced E-cadherin expression was significantly related
to infiltrative tumour growth (P = 0.02), higher histological
grade (P < 0.0001), higher degree of invasion (P = 0.002)
and lymph node metastasis (P = 0.047). Reduced b-cateninanine mammary tumours. (A) Tubulopapillary carcinoma with preserved
negative for E-cadherin expression, whereas non-neoplastic epithelial cells
) Complex carcinoma showing reduced membranous b-catenin expression
Table 1
Association between E-cadherin, P-cadherin and b-catenin expression and clinicopathological parameters
Clinicopathological
parameter
n E-cadherin b-Catenin P-cadherin
Pra Rdb Pr Rd 0 1 2 3
Tumour sizec
<3 cm 22 14 (63.6%) 8 (36.4%) 8 (36.4%) 14 (63.6%) 4 (18.2%) 5 (22.7%) 7 (31.8%) 6 (27.3%)
3–5 cm 26 16 (61.5%) 10 (38.5%) 16 (61.5%) 10 (38.5%) 3 (11.5%) 5 (19.2%) 7 (26.9%) 11 (42.3%)
>5 cm 16 7 (43.8%) 9 (56.3%) 5 (31.3%) 11 (68.8%) 2 (12.5%) 2 (12.5%) 3 (18.8%) 9 (56.3%)
P 0.43 0.1 0.77
Ulceration
Absent 55 32 (58.2%) 23 (41.8%) 26 (47.3%) 29 (52.7%) 7 (12.7%) 12 (21.8%) 15 (27.3%) 21 (38.2%)
Present 10 6 (60%) 4 (40%) 4 (40%) 6 (60%) 2 (20%) 1 (10%) 2 (20%) 5 (50%)
P 0.98 0.74 0.73
Histological type
Solid carcinoma 22 9 (40.9%) 13 (59.1%) 8 (36.4%) 14 (63.6%) 6 (27.3%) 6 (27.3%) 5 (22.7%) 5 (22.7%)
Tubulopapillary
carcinoma
12 10 (83.3%) 2 (16.7%) 8 (66.7%) 4 (33.3%) 1 (8.3%) 2 (16.7%) 3 (25%) 6 (50%)
Complex carcinoma 12 10 (83.3%) 2 (16.7%) 6 (50%) 6 (50%) 1 (8.3%) 4 (33.3%) 3 (25%) 4 (33.3%)
Carcinosarcoma 12 6 (50%) 6 (50%) 6 (50%) 6 (50%) 0 1 (8.3%) 3 (25%) 8 (66.7%)
Spindle cell
carcinoma
4 3 (75%) 1 (25%) 2 (50%) 2 (50%) 0 0 2 (50%) 2 (50%)
Sarcoma 3 0 3 (100%) 0 3 (100%) 1 (33.3%) 0 1 (33.3%) 1 (33.3%)
P 0.01 0.38 0.44
Mode of growth
Expansile 11 10 (90.9%) 1 (9.1%) 7 (63.6%) 4 (36.4%) 2 (18.2%) 5 (45.5%) 3 (27.3%) 1 (9.1%)
Infiltrative 54 28 (51.9%) 26 (48.1%) 23 (42.6%) 31 (57.4%) 7 (13%) 8 (14.8%) 14 (25.9%) 25 (46.3%)
P 0.02 0.32 0.04
Necrosis
Absent 6 5 (83.3%) 1 (16.7%) 4 (66.7%) 2 (33.3%) 0 1 (16.7%) 4 (66.7%) 1 (16.7%)
Present 59 33 (55.9%) 26 (44.1%) 26 (44.1%) 33 (55.9%) 9 (15.3%) 12 (20.3%) 13 (22%) 25 (42.4%)
P 0.38 0.40 0.1
Histological graded
Grade I 4 4 (100%) 0 4 (100%) 0 1 (25%) 1 (25%) 1 (25%) 1 (25%)
Grade II 18 17 (94.4%) 1 (5.6%) 12 (66.7%) 6 (33.3%) 2 (11.1%) 4 (22.2%) 5 (27.8%) 7 (38.9%)
Grade III 40 17 (42.5%) 23 (57.5%) 14 (35%) 26 (65%) 6 (15%) 8 (20%) 10 (25%) 16 (40%)
P <0.0001 0.006 0.99
Invasione
Stage 0 11 11 (100%) 0 9 (81.8%) 2 (18.2%) 1 (9.1%) 5 (45.5%) 3 (27.3%) 2 (18.2%)
Stage I 11 8 (72.7%) 3 (27.3%) 5 (45.5%) 6 (54.5%) 1 (9.1%) 1 (9.1%) 5 (45.5%) 4 (36.4%)
Stage II 43 19 (44.2%) 24 (55.8%) 16 (37.2%) 27 (62.8%) 7 (16.3%) 7 (16.3%) 9 (20.9%) 20 (46.5%)
P 0.002 0.03 0.22
Lymph node metastasisf
Absent 27 20 (74.1%) 7 (25.9%) 13 (48.1%) 14 (5.9%) 3 (11.1%) 8 (29.6%) 9 (33.3%) 7 (25.9%)
Present 25 11 (44%) 14 (56%) 13 (52%) 12 (48%) 3 (12%) 3 (12%) 5 (20%) 14 (56%)
P 0.047 0.99 0.13
Probability (P) values in bold are significant.
a Preserved.
b Reduced.
c Tumour size was available in 64 cases.
d According to the Nottingham method for human breast tumours (Elston and Ellis, 1998).
e According to Gilbertson et al. (1983).
f Lymph nodes were available in 52 cases.
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(P = 0.006) and degree of invasion (P = 0.03). Anomalous
expression of P-cadherin was associated only with invasion
(P = 0.04).
When proliferation indices (mitotic index and Ki-67
index) were compared with expression patterns of the cad-
herins and b-catenin, there were significant differences only
between higher mitotic counts and reduced expression ofE-cadherin (P = 0.03) and b-catenin (P = 0.003) (Table
2). No significant differences were found between P-cad-
herin groups.
Tumours with reduced expression of E-cadherin and b-
catenin were associated with significantly shorter survival
times for both DFS (E-cadherin: P = 0.0263; b-catenin:
P = 0.0095) and OS (E-cadherin: P = 0.0245; b-catenin:
P = 0.0113) (Fig. 2). There was no significant association
Table 2
Association between E-cadherin, P-cadherin and b-catenin expression and
proliferation indices
n Mitotic index Ki-67 index
Mean ± standard
deviation
Mean ± standard
deviation
E-cadherin
Preserved 33 0.88 ± 0.58 24.98 ± 9.84
Reduced 27 1.27 ± 0.75 29.69 ± 9.31
P 0.03 0.064
b-Catenin
Preserved 25 0.75 ± 0.49 24.54 ± 10.59
Reduced 35 1.27 ± 0.49 28.92 ± 8.93
P 0.003 0.088
P-cadherin
<10% 8 1.45 ± 0.84 26.85 ± 8.75
10–25% 12 0.76 ± 0.42 24.1 ± 7.52
26–50% 15 1.02 ± 0.68 27.97 ± 9.93
>50% 25 1.09 ± 0.72 28.09 ± 11.18
P 0.179 0.693
Probability (P) values in bold are significant.
Fig. 2. Kaplan–Meier overall survival and disease-free survival curves of group
(C, D).
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OS (Fig. 3).
When tumours were grouped according to combined
patterns of expression of E-cadherin/P-cadherin, b-cate-
nin/P-cadherin and E-cadherin/b-catenin, there were sig-
nificant differences in histological grade III (P = 0.005),
invasion grades I and II (P = 0.045) and lymph node
metastasis (P = 0.029) for E-cad/P-cad (/+) cases, but
no significant differences for E-cad/P-cad (+/) or E-cad/
P-cad (+/+) tumours (Supplementary Table 1). There
was a significant association between b-cat/P-cad (/+)
immunoreactivity and less differentiated tumours (P =
0.016) when compared to other groups (Supplementary
Table 2). Loss/reduction of immunoreactivity for E-cad-
herin, b-catenin, or both, was significantly associated with
less differentiated tumours (P = 0.003), higher invasive
grade (P = 0.02) and lymph node metastases (P = 0.043)
(Supplementary Table 3). No statistical differences were
found with the remaining variables.s with preserved and reduced expression of E-cadherin (A, B) and b-catenin
Fig. 3. Kaplan–Meier overall survival (A) and disease-free survival (B)
curves of cases with <10% (0), 10–25% (1), 25–50% (2) or >50% (3) P-
cadherin positive cells.
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Altered expression or absence of expression of the cad-
herin–catenin complex results in decreased adhesion of
cells and has been implicated in tumorigenesis, particularly
tumour cell invasion (Wijnhoven et al., 2000). Several pre-
vious reports have described the expression of cadherins
and/or associated proteins in canine mammary gland
tumours, but the patterns of expression of E-cadherin, P-
cadherin and b-catenin have not been correlated with a
wide range of clinicopathological features, including sur-
vival (Restucci et al., 1997; Reis et al., 2003; Gama et al.,
2004; Brunetti et al., 2005; De Matos et al., 2007).
The present study demonstrated reduced membranous
expression of E-cadherin and b-catenin in malignant canine
mammary tumours compared to the normal mammary
gland, suggesting that down-regulation of these molecules
is a common event in canine mammary tumours. This find-
ing is supported by other recent studies on canine mam-
mary tumours (Brunetti et al., 2005; De Matos et al.,2007) and human breast cancer (Park et al., 2007).
Although P-cadherin is not expressed in normal mammary
epithelial cells, a subset of canine mammary tumours
exhibited aberrant P-cadherin expression, as previously
reported (Gama et al., 2004).
A relationship between E-cadherin and b-catenin
expression was observed in canine mammary tumours in
this study, corroborating previous reports of co-expression
of these adhesion molecules in canine mammary tissue
(Brunetti et al., 2005; De Matos et al., 2007) and human
breast tissue (Gillet et al., 2001; Yoshida et al., 2001). This
finding is consistent with the formation of adhesion com-
plexes on the cell membrane. Some human breast cancer
studies have reported an inverse correlation between loss
of E-cadherin and aberrant P-cadherin immunoreactivity
(Palacios et al., 1995; Peralta Soler et al., 1999; Gamallo
et al., 2001), whereas we found no association between P-
cadherin and other adhesion molecules.
In this study, reduced membranous expression of E-cad-
herin was significantly associated with histological type,
poor differentiation, high invasiveness, high index of prolif-
eration and lymph node metastasis. Previous studies on
canine mammary tumours have made similar observations
(Restucci et al., 1997; Reis et al., 2003; Brunetti et al., 2005;
De Matos et al., 2007). Together with our results, this sug-
gests a possible role for E-cadherin-mediated adhesion in
preventing invasion and metastasis in canine mammary
tumours, corroborating some studies in human breast can-
cer (Bankfalvi et al., 1999; Madhavan et al., 2001).
However, other studies on human breast cancer have
not confirmed such a relationship (Palacios et al., 1995;
Bukholm et al., 1998; Kovacs et al., 2003) or have associ-
ated preservation of expression of E-cadherin with lymph
node metastasis (Gillet et al., 2001; Howard et al., 2005).
In contrast to the present study, one previous report on
canine mammary tumours showed no association between
reduced E-cadherin expression and high histological grade
(Matos et al., 2006). Our study identified an association
between expression of E-cadherin and mitotic index,
whereas no such association was identified by Brunetti
et al. (2005). In human cancer studies, we also find oppos-
ing results for differentiation (Siitonen et al., 1996; Kovacs
et al., 2003; Howard et al., 2005) and proliferation (Char-
pin et al., 1999; Fricke et al., 2003). Sample selection (his-
tological type, stage, tumour grade), number of cases
analysed and differences in staining evaluation may indi-
vidually or in combination be held responsible for the
observed discrepancies between different studies.
Reduced membranous b-catenin expression was found
to be significantly associated with high grade and highly
invasive tumours. These findings confirm a previous study
(Brunetti et al., 2005) but contradict another (De Matos
et al., 2007). In the present study, we found no association
between the loss of b-catenin expression and the presence
of lymph node metastases, which supports similar findings
in canine (De Matos et al., 2007) and human studies (Buk-
holm et al., 1998; Gonzalez et al., 1999; Yoshida et al.,
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b-catenin reduction and high mitotic index, in contrast to a
previous study in dogs (Brunetti et al., 2005).
The prognostic significance of E-cadherin and b-catenin
expression in terms of survival of dogs with mammary
carcinoma is unclear. Our data show that loss/reduction
of E-cadherin and b-catenin expression is significantly
associated with shorter OS and DFS, in contrast to previ-
ous findings by Brunetti et al. (2005). In human breast can-
cer studies, assessment of down-regulation of E-cadherin
and catenins as prognostic markers of breast carcinoma
has also proven problematic. Some authors claim that E-
cadherin and b-catenin represent valuable prognostic
markers (Siitonen et al., 1996; Dollet-Filhard et al., 2006;
Park et al., 2007), whereas others have found no associa-
tion between these molecules and survival time (Peralta
Soler et al., 1999; Yoshida et al., 2001).
These conflicting results may reflect the current poor
understanding of the dynamics of cell–cell adhesion. This
process seems to be regulated at various levels, including
gene transcription, protein stability and post-translational
modification of the cadherin/catenin complex, in particular
by phosphorylation of b-catenin. Besides its function in
establishing tight cell adhesion, b-catenin plays a major
role in cell signalling through interactions with receptor
tyrosine kinases and transcription factors of the Lef/Tcf
family, suggesting a dual role as a tumour suppressor
and as an oncogene in human cancers (Wijnhoven et al.,
2000).
Aberrant expression of P-cadherin was associated with
invasion, but not with a higher invasion grade, which also
takes into account vessel and/or lymph node involvement.
Our results with canine mammary malignant tumours do
not reflect some in vitro studies in human breast (Paredes
et al., 2004) and pancreatic (Taniuchi et al., 2005) cancer
cell lines, which suggest a proinvasive role for P-cadherin,
through its interaction with signalling molecules such as
p120ctn (Taniuchi et al., 2005).
In the present series, we did not find further associations
between P-cadherin expressions and other clinicopatholog-
ical variables or proliferation labelling indices. In our pre-
vious study, we described an association with tumour type
(Gama et al., 2004), which was not confirmed in this larger
series. In human cancer studies we also find contradictory
results, probably related with sample selection. Paredes
et al. (2005) found no significant correlation with histolog-
ical type, although some authors suggested that P-cadherin
was related with some special tumour types, such as med-
ullary and metaplastic carcinomas (Palacios et al., 1995).
The present work supports our previous study, which
did not find a statistically significant difference between
P-cadherin aberrant expression and differentiation grade
(Gama et al., 2004). However, in recent studies on human
breast cancer, P-cadherin expression was significantly asso-
ciated with increased histological grade (Palacios et al.,
1995; Peralta Soler et al., 1999; Gamallo et al., 2001; Pare-
des et al., 2002, 2005; Kovacs et al., 2003). The small num-ber of grade I tumours in our study may not have provided
sufficient statistical power to establish an association.
Some human breast cancer studies (Palacios et al., 1995;
Kovacs et al., 2003; Paredes et al., 2005) also failed to find
a correlation between anomalous expression of P-cadherin
and the presence of lymph node metastases. However,
other studies have described an association with highly
proliferative tumours (Paredes et al., 2005), lymph node
metastases (Gamallo et al., 2001) and poor prognosis (Per-
alta Soler et al., 1999; Gamallo et al., 2001; Paredes et al.,
2005). Although several authors suggested a possible role
for P-cadherin in promoting aggressive tumour cell behav-
iour (Peralta Soler et al., 1999; Gamallo et al., 2001; Pare-
des et al., 2002, 2005), the biological significance of the
anomalous P-cadherin in breast cancer is still poorly
understood. As P-cadherin is expressed only by myoepithe-
lial cells in normal breast tissue, the presence of this mole-
cule might indicate a basal/myoepithelial differentiation
(Peralta Soler et al., 1999), which has been associated with
a poor outcome in human breast cancer (van de Rijn et al.,
2002).
Despite some similarities with human breast cancer,
canine mammary tumours are frequently associated with
myoepithelial differentiation (Misdorp, 2002), which might
explain the high percentage of P-cadherin positive tumours
in our series. Although no correlation was found in the
present study, we propose additional studies including a
large series of simple carcinomas in order to investigate if
P-cadherin expression is able to identify a subset of carci-
nomas with a particularly poor prognosis.
It is important to note that alterations in any component
may lead to disrupted function of adhesion complexes.
When we studied E-cadherin/b-catenin combinations, we
found that the loss or reduction of at least one of these
molecules was associated with less differentiated, highly
invasive tumours, frequently with lymph node metastasis,
supporting previous canine (Brunetti et al., 2005) and
human studies (Bukholm et al., 1998; Wijnhoven et al.,
2000). However, future studies are needed with a larger ser-
ies and a longer follow up to investigate these interrelation-
ships and correlate them with distinct tumour behaviours
in the canine mammary gland.Conclusions
The study has demonstrated altered expression of inter-
cellular adhesion molecules in canine mammary malignant
tumours. There were significant associations between
reduced E-cadherin expression and some known prognostic
parameters, such as tumour type, histological grade, inva-
siveness and lymph node metastasis and between reduced
b-catenin expression and histological grade and invasive-
ness. Preserved expression of these molecules was associ-
ated with tumours of low mitotic index and with a better
clinical outcome. We were also able to confirm aberrant
P-cadherin expression in malignant mammary tumours,
52 A. Gama et al. / The Veterinary Journal 177 (2008) 45–53which was associated with an infiltrative tumour growth,
but with no relation to other clinicopathological variables.
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